This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the SEER program tumor registries in the creation of the SEER-Medicare database.
van den BerghRCRoemelingSRoobolMJ. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol2009;55:1–8.
TosoianJJTrockBJLandisP. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011;29:2185–2190.
Dall’EraMAKonetyBRCowanJE. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer2008;112:2664–2670.
MoyerVA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012;157:120–134.
HayesJHOllendorfDAPearsonSD. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA2010;304:2373–2380.
Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2009) National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2012 based on the November 2011 submission. Available at: http://appliedresearch.cancer.gov/seermedicare/obtain/requests.html.
WarrenJLKlabundeCNSchragD. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care2002;40(8 Suppl):IV-3–18.
Actuarial Life Table Year 2007. Social Security Administration. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed September 19 2012.
WalterLCCovinskyKE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA2001;285:2750–2756.
QuanHSundararajanVHalfonP. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care2005;43:1130–1139.
NguyenPLGuXLipsitzSR. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol2011;29:1517–1524.
AlbertsenPCHanleyJAFineJ. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA2005;293:2095–2101.
KingCRMcNealJEGillHPrestiJCJr. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys2004;59:386–391.
San FranciscoIFDeWolfWCRosenS. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol2003;169:136–140.
DivrikRTErogluASahinA. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urol Oncol2007;25:376–382.
EmiliozziPMaymoneSPaternoA. Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol2004;172(6 Pt 1):2224–2226.
MoussaASKattanMWBerglundR. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int2010;105:352–358.
SundiDRossAEHumphreysEB. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?J Clin Oncol2013;31:2991–2997.
D’AmicoAVManolaJLoffredoM. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA2004;292:821–827.
BollaMGonzalezDWardeP. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997;337:295–300.
UnoHNakanoMEharaHDeguchiT. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. Urology2008;71:23–27.
BittencourtLKBarentszJOde MirandaLCGasparettoEL. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol2012;22:468–475.
FreedlandSJGerberLReidJ. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys2013;86:848–853.
CuzickJSwansonGPFisherG. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol2011;12:245–255.
KnezevicDGoddardADNatrajN. Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics2013;14:690.
SandaMGDunnRLMichalskiJ. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med2008;358:1250–1261.
JacobsBLZhangYSchroeckFR. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA2013;309:2587–2595.
KlotzLZhangLLamA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010;28:126–131.
2012 Budget Request. National Cancer InstituteWeb site. Available at: http://www.cancer.gov/aboutnci/budget_planning_leg/plan-2012/2012budgetrequest. Accessed May 2 2013.
CooperbergMRBroeringJMCarrollPR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol2010;28:1117–1123.
FeliuJJimenez-GordoAMMaderoR. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst2011;103:1613–1620.
FroehnerMKochRLitzRJ. Which patients are at the highest risk of dying from competing causes </= 10 years after radical prostatectomy?BJU Int2012;110:206–210.
FowlerFJJrMcNaughton CollinsMAlbertsenPC. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA2000;283:3217–3222.
AizerAAPalyJJZietmanAL. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol2012;30:3071–3076.
MooreMJO’SullivanBTannockIF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol1988;6:1736–1745.
FalitBPGrossCPRobertsKB. Integrated prostate cancer centers and over-utilization of IMRT: a close look at fee-for-service medicine in radiation oncology. Int J Radiat Oncol Biol Phys2010;76:1285–1288.
MitchellJMSunshineJH. Consequences of physicians’ ownership of health care facilities--joint ventures in radiation therapy. N Engl J Med1992;327:1497–1501.
AnscherMSAnscherBMBradleyCJ. The negative impact of stark law exemptions on graduate medical education and health care costs: the example of radiation oncology. Int J Radiat Oncol Biol Phys2010;76:1289–1294.
Medicare Advantage 2012 Data Spotlight: Enrollment Market Update. The Henry J. Kaiser Family FoundationWeb site. Available at: http://www.kff.org/medicare/8323.cfm. Accessed September 23 2012.